The benefit builds over years — earlier trials stopped before it became visible.
Somewhere in the gap between a clean bill of health and a first heart attack, there is a window — and a new clinical trial suggests that window is exactly where a powerful cholesterol drug should be used.
The VESALIUS-CV trial, presented as a late-breaking finding at the American Heart Association's Scientific Sessions 2025 in New Orleans, tested whether adding evolocumab — a PCSK9 inhibitor that works by blocking a liver protein to drive down LDL cholesterol — to an already aggressive cholesterol-lowering regimen could protect people who had never yet had a heart attack or stroke but were clearly headed toward one. The answer, after tracking more than 12,000 patients across 33 countries over an average of 4.6 years, was a firm yes.
The trial enrolled 12,257 adults, average age 66, all of whom had either atherosclerotic cardiovascular disease or high-risk diabetes, and all of whom had elevated LDL cholesterol of at least 90 mg/dL. Crucially, none had previously suffered a major cardiac event. About two-thirds qualified based on arterial disease — coronary, peripheral, or cerebrovascular — and half had diabetes; many fell into both categories. Roughly 72 percent were already on a high-intensity lipid-lowering regimen when they enrolled. Participants were randomized to receive either 140 milligrams of evolocumab injected under the skin every two weeks, or a placebo on the same schedule.
The results were striking. Patients receiving evolocumab saw a 25 percent reduction in the combined risk of coronary heart disease death, heart attack, or ischemic stroke compared to those on placebo. A broader endpoint that added ischemia-driven arterial revascularization showed a 19 percent reduction. Heart attacks specifically fell by 36 percent. Death from cardiovascular causes ran at 2.8 percent in the evolocumab group versus 3.6 percent in the placebo group, and all-cause mortality was 7.9 percent versus 9.7 percent — differences that, while not the trial's primary endpoints, point in a consistent direction.
On the cholesterol numbers themselves, the drug performed as expected. Patients entering the trial had a median LDL of 115 mg/dL. By 48 weeks, those on evolocumab had driven that figure down by nearly 55 percent, to a median of 45 mg/dL. Those on placebo stayed roughly where they started, at a median of 109 mg/dL.
Lead author Erin A. Bohula, an assistant professor of medicine at Harvard Medical School and Brigham and Women's Hospital, called the findings the first demonstration that a PCSK9 inhibitor — or any non-statin drug — can improve cardiovascular outcomes in patients who haven't yet had a heart attack or stroke but are already being treated aggressively. She noted that the benefit per unit of LDL reduction tracked closely with what statin trials have historically shown, and offered a reason why earlier PCSK9 inhibitor studies may have undersold the drug's potential: they simply didn't run long enough. The cardiovascular benefits of lowering LDL don't arrive immediately; they accumulate over time, and a 4.6-year follow-up appears to have been long enough to capture them.
The findings held up across key subgroups, including the roughly one-third of participants who had high-risk diabetes without qualifying arterial disease — a population that has historically been harder to treat to aggressive LDL targets. Bohula and her colleagues concluded that the data support pushing LDL levels down to around 40 mg/dL as a target for preventing a first major event, not just managing patients who have already had one.
The trial was not without its caveats. The study population was 93 percent white, limiting how confidently the results can be extended to other racial and ethnic groups. A small slice of participants — about 8 percent — weren't on any cholesterol-lowering therapy at baseline, which complicates the picture slightly. And then there is the practical obstacle that looms over all of this: evolocumab is expensive, and insurance coverage for PCSK9 inhibitors remains inconsistent. The clinical case for earlier use is now considerably stronger. Whether payers follow the science is a separate question entirely.
Notable Quotes
These results represent the first demonstration of improved cardiovascular outcomes with a PCSK9 inhibitor — or any non-statin — in patients without a previous heart attack or stroke who are already on a high-intensity lipid-lowering regimen.— Erin A. Bohula, M.D., D.Phil., Harvard Medical School and Brigham and Women's Hospital
There is a well-described delay in the onset of cardiovascular benefits from lowering LDL-C, and it takes time for those benefits to become measurable — which may explain why shorter trials underestimated the long-term effect.— Erin A. Bohula, lead study author, VESALIUS-CV trial
The Hearth Conversation Another angle on the story
What makes this trial different from earlier PCSK9 inhibitor studies?
Most of the earlier work focused on people who had already had a heart attack or stroke. This one specifically excluded them — it's asking whether the drug can prevent a first event, not a second.
And the answer is yes?
Clearly yes, by the numbers. A 36 percent reduction in heart attacks, a 25 percent reduction in the combined endpoint of coronary death, heart attack, or stroke. That's not a marginal signal.
Why did it take this long to see that?
Bohula's explanation is that LDL reduction doesn't pay off immediately. The benefit builds over years. Earlier trials were shorter, and they may have stopped before the full effect became visible.
So the length of follow-up — 4.6 years — was actually part of why this worked?
That's the argument. And it fits with what we know from statin research. The Cholesterol Treatment Trialists' data shows the same pattern: the longer you lower LDL, the more the risk curves separate.
Who were these patients exactly?
People in a dangerous middle zone — arterial disease or high-risk diabetes, elevated LDL, no prior heart attack or stroke. Two-thirds were already on aggressive statin therapy. These aren't undertreated patients. They're patients where the current standard of care wasn't enough.
What does it mean to target an LDL of 40 mg/dL?
It's lower than most guidelines currently push for in primary prevention. The trial's evolocumab group landed at a median of 45 mg/dL. That's the territory the researchers are now saying should be the goal.
Is there a catch?
The obvious one is access. Evolocumab is FDA-approved, but PCSK9 inhibitors are expensive and insurance coverage is patchy. The science is ahead of the system.
And the population gap?
Ninety-three percent of participants identified as white. That's a real limitation. The researchers themselves say future studies need to confirm whether these results hold across more diverse groups.